By Josh White
Date: Monday 29 Apr 2024
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
Total Voting Rights | 01-May-2024 | 07:00 | RNS |
2023 Annual Report and Accounts | 30-Apr-2024 | 17:00 | RNS |
Prelim Results for Y/E 2023 - REPLACEMENT | 29-Apr-2024 | 09:38 | RNS |
Preliminary results for the year ended 31 Dec 2023 | 29-Apr-2024 | 07:00 | RNS |
Total Voting Rights | 02-Apr-2024 | 07:00 | RNS |
Need to know: Opec cuts forecast ... Tesco cuts ... | 16-Aug-2008 | Times |
Need to know | 10-May-2008 | Times |
DSG International may be losing its spark | 12-Feb-2008 | Telegraph |
Oxford BioMedica clinches $690m licensing deal f... | 29-Mar-2007 | The Independent |
Oxford Biomedica seals €518m deal with Sanofi ov... | 29-Mar-2007 | Times |
No recent information was found.
Currency | UK Pounds |
Share Price | 300.00p |
Change Today | 13.00p |
% Change | 4.53 % |
52 Week High | 470.00 |
52 Week Low | 166.80 |
Volume | 325,249 |
Shares Issued | 100.00m |
Market Cap | £300.00m |
RiskGrade | 125 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 3 |
Neutral | 6 |
Sell | 0 |
Strong Sell | 0 |
Total | 10 |
No dividends found |
Time | Volume / Share Price |
16:39 | 35,562 @ 298.33p |
16:35 | 50,193 @ 300.00p |
16:35 | 255 @ 300.00p |
16:35 | 1,428 @ 300.00p |
16:35 | 378 @ 300.00p |
You are here: research